Gildan Q2 Adjusted EPS $1.28, Raises 2026 Guidance to $4.65–$4.75, Announces A$700M HAA Divestiture
GIL is trading near its 52-week low of $46 (13% above the low).
Summary
Gildan reported Q2 adjusted EPS of $1.28, raised full-year guidance, and announced the sale of its Australian business for ~A$700M, strengthening its deleveraging path.
Key Events · Earnings and Guidance · GIL
-
Q2 Earnings Beat, Guidance Raised
Adjusted EPS of $1.28 vs. $0.97 a year ago; full-year 2026 adjusted EPS guidance raised to $4.65–$4.75, reflecting strong HanesBrands integration and margin expansion.
-
HanesBrands Australian Business Divestiture
Definitive agreement to sell HAA for ~A$700M (~$490M), with proceeds earmarked for debt repayment, accelerating return to target leverage and eventual share buybacks.
-
Impairment and Integration Costs
Recorded a $153M impairment on HAA assets held for sale and $151M in restructuring/acquisition costs YTD, primarily from facility closures and inventory step-up, weighing on GAAP earnings.
-
Tariff Refund Windfall
Recognized ~$30M in IEEPA tariff refunds in Q2, with an additional ~$180M expected in Phase II, providing a significant tailwind to margins and cash flow.
Analysis · GIL · Manufacturing
Gildan delivered a strong Q2, with adjusted EPS of $1.28 beating expectations and full-year guidance raised to $4.65–$4.75. The HanesBrands acquisition is driving a 72% sales surge, and adjusted gross margins expanded 300 bps to 34.5%. The company also announced a definitive agreement to sell its Australian business for ~A$700M, which will accelerate debt reduction and a return to share buybacks. However, a $153M impairment on the Australian assets and a net debt leverage ratio of 3.2x highlight integration and balance sheet pressures. The results come amid an ongoing activist short-seller campaign, making the strong operational performance and divestiture a critical rebuttal.
At the time of this filing, GIL was trading at $52.00 on NYSE in the Manufacturing sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $46.00 to $73.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.